• Frontline Therapies for MM
• Evolving Strategies in CLL
• Clinical Advances for Patients With MDS

1.5 AMA PRA Category 1 Credits™
Expiration date: May 28, 2009

• Optimizing Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A New Era

1.5 AMA PRA Category 1 Credits™
Expiration date: May 28, 2009

• Dose-Intense and Dose-Dense Regimens in Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma

1.5 AMA PRA Category 1 Credits™
Expiration date: May 27, 2009

• Novel Agents for Hematologic Malignancies

1.25 AMA PRA Category 1 Credits™
Expiration date: May 27, 2009

• Optimizing Biologic Therapies in Low-Grade Lymphoma
• Improving Outcomes in DLBCL by Altering Current Regimens
• Biologic Therapy in CLL: Current Data and Ongoing Studies
• Novel Anti-CD20 Antibodies in NHL
• Current Trends in Antiangiogenic Therapy in NHL
• Therapeutic Approaches to Targeting the Apoptotic Pathway in Lymphoma

1 AMA PRA Category 1 Credit™
Expiration date: May 15, 2009

• HDACIs in PTCL

1 AMA PRA Category 1 Credit™
Expiration date: May 5, 2009

• Hereditary Hemochromatosis and Iron Overload Disorders
• Mechanisms of Action of Iron Chelating Agents
• Current Perspectives in Measuring LIC
• Managing Iron Overload in Transfusion-Dependent Patients

1 AMA PRA Category 1 Credit™
Expiration date: April 4, 2009

• Romidepsin in MF and Histologic Large-Cell Transformation

1 AMA PRA Category 1 Credit™
Expiration date: March 17, 2009

• Update on Histone Deacetylase Inhibitors in the Treatment of T-Cell Lymphoma and Multiple Myeloma

0.5 AMA PRA Category 1 Credit™
Expiration date: March 03, 2009

• Update on Targeted Therapies in Chronic Myeloid Leukemia

0.5 AMA PRA Category 1 Credit™
Expiration date: March 03, 2009

• Current and Novel Treatment Strategies for Newly Diagnosed Multiple Myeloma

0.5 AMA PRA Category 1 Credit™
Expiration date: February 15, 2009

• Introduction and Overview
• Expert Interviews: A Conversation on Practical Updates in the Management Multiple Myeloma With Dr. Asher Chanan-Khan and Dr. Sagar Lonial
• Integration of Anthracyclines Into the Management of Patients With Relapsed/Refractory Multiple Myeloma
• Advances in Treatment Options for Patients With Newly Diagnosed Multiple Myeloma

1 AMA PRA Category 1 Credit™
Expiration date: December 7, 2008

• Standard of Care in Aggressive Lymphomas: R-CHOP Schedule
• Maintenance Rituximab in Indolent Lymphomas
• Optimal Treatment Option in MCL

1 AMA PRA Category 1 Credit™
Expiration date: November 20, 2008

• Bifunctional Alkylators Plus Other Cytotoxic Agents in Lymphomas
• Incorporating Proteasome Inhibitors Into Treatment of MCL
• Novel Approaches to CLL: MoAbs Plus Novel Cytotoxic Agents
• The Role of Novel Antibodies in Hematologic Malignancies

1 AMA PRA Category 1 Credit™
Expiration date: November 20, 2008

• Recent Advances in NHL
• Phase III Trial of R-HDS Compared to R-CHOP in High-Risk FL
• Maintenance Rituximab in Elderly Patients With DLBCL
• Phase II Study of Lenalidomide in Relapsed/Refractory NHL
• Phase II Study of Bortezomib/R-CHOP in Treatment-Naive BCL
• Low Doses of hA20 in Relapsed/Refractory NHL

1 AMA PRA Category 1 Credit™
Expiration date: October 31, 2008

• Emerging Strategies for Eradicating MRD in CLL
• Role of Alemtuzumab in Transplantation for CLL

1 AMA PRA Category 1 Credit™
Expiration date: October 31, 2008

• CAAS Effector Mechanisms of Antitumor Antibodies

1 AMA PRA Category 1 Credit™
Expiration date: October 15, 2008

• Modulating Epigenetic Mechanisms in Hematologic Malignancies
• Epigenetic Therapy in Hematologic Malignancies
• HDACIs in Hematologic Malignancies Future Directions and Challenges for HDAC Inhibition
• Bcr-Abl TKIs in CML and Ph⁺ ALL
• MK-0457 in Imatinib-Resistant CML

1 AMA PRA Category 1 Credit™
Expiration date: September 30, 2008

• Alemtuzumab in Relapsed/Refractory CLL
• Genomic Profiling in CLL

1 AMA PRA Category 1 Credit™
Expiration date: September 15, 2008

• Small-Molecule Inhibitors in TCL

0.5 AMA PRA Category 1 Credit^™
Expiration date: July 31, 2008